Summary & Overview
CPT 28173: Radical Resection of Metatarsal for Tumor
CPT code 28173 denotes a radical surgical resection of a metatarsal bone and adjacent tissue to remove a tumor, typically performed for malignant or aggressive benign lesions requiring wide excision. This code is used to document substantial forefoot oncologic surgery and has implications for surgical planning, site-of-service decisions, and payer coverage determinations nationwide. Key national payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise clinical and billing overview of the procedure, understand which payers are commonly relevant for claims involving this code, and find a summary of the clinical context in which the code is used. The publication covers benchmarks where available, common billing considerations, and recent policy or coverage issues that affect authorization and reimbursement practices. It also outlines typical settings where the procedure is performed and the general clinical rationale for radical resection in metatarsal tumors. Data not available in the input for specific payer rates, associated taxonomies, and ICD-10 pairings is noted where applicable.
Billing Code Overview
CPT code 28173 describes a radical resection of a metatarsal bone performed to remove a tumor. The procedure involves surgical removal of the affected metatarsal and surrounding soft tissue, often with a wide margin of normal tissue excised when the lesion is malignant, to reduce the risk of residual tumor.
Service type: Surgical oncology / orthopedic oncology procedure
Typical site of service: Hospital operating room or ambulatory surgery center, depending on the case complexity and need for inpatient care.
Clinical & Coding Specifications
Clinical Context
A 58-year-old male presents with a painful, enlarging mass over the dorsal aspect of the forefoot centered at the second metatarsal. Imaging with foot radiographs and MRI demonstrates an aggressive lesion involving the second metatarsal with cortical destruction and soft-tissue extension. Core needle biopsy returns a diagnosis of osteosarcoma of the metatarsal. The orthopedic foot and ankle oncology surgeon schedules the patient for a radical metatarsal resection with wide margins to achieve local tumor control. The typical clinical workflow includes preoperative oncology consultation, staging imaging (chest CT to rule out pulmonary metastases), preoperative anesthesia evaluation, informed consent for limb-sparing resection versus possible amputation, intraoperative pathologic margin assessment as available, the surgical resection of the affected metatarsal and adjacent soft tissue, reconstruction or soft-tissue coverage as indicated, and postoperative admission for pain control, wound monitoring, and coordination with medical oncology for adjuvant therapy planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Normal procedure when performed for a surgical service | Use when the service is performed as the primary procedure without unusual circumstances. |
22 |